RAPID MICRO BIOSYSTEMS, INC. — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Rapid Micro Biosystems reported Q2 2026 total revenue of $8.1M (up 10.9% YoY from $7.3M). Gross margin reached a record 15% ($1.2M) vs. 3.8% in Q2 2025—an 11-percentage-point improvement. The company placed 4 Growth Direct systems, completed 9 validations, and achieved 200th global system placement. Recurring revenue grew 14% to $5.0M (63% of total). Cash position declined to ~$20M (from $38.6M at year-end 2025). Net loss was $12.9M ($0.27/share); non-GAAP adjusted EBITDA loss was $10.3M. Full-year 2026 guidance reaffirmed: revenue $37–41M, 30–38 system placements, ~20% gross margin; validation guidance increased to ≥27 from 25.
Why this rating
Modest growth (11% revenue, 4 units/quarter) and margin recovery offset by ongoing large losses ($12.9M quarterly). Cash burn, heavy OpEx ($13.5M), and low absolute scale relative to $103.6M market cap create sustainability risk despite operational progress.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.